[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100652359":3},{"organization":4,"armGroups":7,"interventions":10,"overallOfficials":10,"centralContacts":13,"locations":10,"responsibleParty":23,"collaborators":10,"id":27,"slug":28,"hasResults":29,"nctId":30,"briefTitle":31,"officialTitle":31,"acronym":10,"eligibilityCriteria":32,"healthyVolunteers":29,"sex":33,"minAge":34,"maxAge":10,"enrollmentInfo":35,"targetDuration":10,"studyType":38,"phases":10,"briefSummary":39,"conditions":40,"keywords":10,"overallStatus":42,"whyStopped":10,"lastUpdateSubmitDate":43,"lastUpdatePostDateStruct":44,"startDateStruct":47,"completionDateStruct":49,"leadSponsor":51,"locationsCount":10},{"fullName":5,"class":6},"Sheikh Zayed Federal Postgraduate Medical Institute","OTHER",[8,11],{"label":9,"type":10,"description":10,"interventionNames":10},"The first group will be of normoalbuminemic post surgical patients receiving cefoperazone\u002Fsulbactam",null,{"label":12,"type":10,"description":10,"interventionNames":10},"The second group will be of hypoalbuminemic post surgical patients receiving cefoperazone\u002Fsulbactam",[14,19],{"name":15,"role":16,"phone":17,"phoneExt":10,"email":18},"Dr. Fatima Aftab, PGR Pharmacology, FPGMI Lahore","CONTACT","+923304262819","fatimaaftabkhosa1999@gmail.com",{"name":20,"role":16,"phone":21,"phoneExt":10,"email":22},"Dr. Mudassara Yaseen HOD Pharmacology FPGMI, Lahore","+923334162630","Drmudassarayaseen@gmail.com",{"type":24,"investigatorFullName":25,"investigatorTitle":26,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Tahira Shaukat","Dr. Fatima Aftab, Post Graduate Trainee","100652359","impact-of-hypoalbuminemia-on-cefoperazonesulbactam-induced-coagulopathy-in-post-operative-surgical-patients-100652359",false,"NCT07773584","Impact of Hypoalbuminemia on Cefoperazone\u002FSulbactam Induced Coagulopathy in Post-Operative Surgical Patients","Inclusion Criteria:\n\n* Patients \\>= 18 years\n* Post-operative surgical patients\n* Receiving cefoperazone\u002Fsulbactam therapy for at least 72 hours.\n* Willing to give informed consent\n\nExclusion Criteria:\n\n* Chronic liver disease\n* History of any inherited coagulation disorder\n* On anticoagulant therapy\n* Any massive blood loss requiring blood transfusion\n* Patients who have been given Vitamin K prior to the start of cefoperazone\u002Fsulbactam therapy\n* Pregnancy","ALL","18 Years",{"count":36,"type":37},108,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to learn whether hypoalbuminemia in post surgical patients receiving cefoperazone\u002Fsulbactam therapy poses them to the risk of developing coagulopathy. It will also study that what are the other risk factors for the development of cefoperazone\u002Fsulbactam induced coagulopathy. The main questions it aims to answer are : • Does hypoalbuminemia increase the risk of cefoperazone\u002Fsulbactam coagulopathy in post operative surgical patients?\n\n* What is the incidence of cefoperazone\u002Fsulbactam induced coagulopathy in normoalbuminemic vs hypoalbuminemic patients.\n* Does renal function, nutritional status, dose and duration of therapy affect coagulopathy development?\n* What are the independent risk factors for the development of cefoperazone\u002Fsulbactam induced coagulopathy? Patients' coagulation tests will be followed during the duration of cefoperazone\u002Fsulbactam therapy to identify coagulation development.",[41],"Hypoalbuminemia and Cefoperazone\u002FSulbactam Induced Coagulopathy","NOT_YET_RECRUITING","2026-08-19",{"date":45,"type":46},"2026-08-21","ACTUAL",{"date":48,"type":37},"2027-04",{"date":50,"type":37},"2027-10",{"name":5,"class":6}]